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Ideally, clinical decision making ought to be based 
on the latest evidence available. However, to keep 
abreast with the continuously increasing number of 
publications in health research, a primary health care 
professional would need to read an unsurmountable 
number of articles every day covered in more than 13 
million references and over 4800 biomedical and health 
journals in Medline alone.1 With the view to address 
this challenge, the systematic review method was 
developed.2 This article provides a practical guide for 
appraising systematic reviews for relevance to clinical 
practice and interpreting meta-analysis graphs as part 
of quantitative systematic reviews.
	
A	 systematic	 review	 is	 a	 synthesis	 of	 primary	 research	
studies	investigating	a	clearly	formulated	clinical	question	
using	systematic,	explicit	and	reproducible	methods.	The	
Cochrane	 Library	 is	 probably	 the	most	 comprehensive	
collection	of	 regularly	updated	systematic	 reviews	 in	 the	
health	field	and	is	freely	accessible	in	Australia.3
	 Some	 systematic	 reviews	 qualify	 for	 a	 quantitative	
statistical	 summary	 of	 comparable	 study	 findings,	
the	meta-analysis.	While	 useful	 guides	 to	 systematic	
rev iew	 methodo logy	 and	 cr i t i ca l 	 appra isa l 	 o f	
systematic	 reviews	 are	 plentiful,4–6	 there	 is	 a	 paucity	
of	 practical	 guides	 to	 appraisal	 of	 meta-analysis	 for	
the	nonstatistician.
	 This	 article	 provides	 a	 practical	 guide	 to	 appraisal	
of	meta-analysis	 graphs,	 and	 has	 been	 developed	 as	
part	 of	 the	 Primary	 Health	 Care	 Research	 Evaluation	
Development	 (PHCRED)	 capacity	 building	 program	 for	
training	 general	 practitioners	 and	 other	 primary	 health	
care	professionals	in	research	methodology.
Critical appraisal of systematic reviews and 
meta-analyses
It	 is	 important	 to	 assess	 the	methods	 and	 quality	 of	
the	 systematic	 review	 and	 appropriateness	 of	 the	
meta-analysis	 before	 diving	 into	 the	 fine	 points	 of	 the	
meta-analysis	 results	 and	drawing	 conclusions	on	patient	
treatment.	Table 1	can	guide	the	assessment.
Meta-analysis graphs
Meta-analysis	 results	 are	 commonly	 displayed	graphically	
as	 ‘forest	 plots’.	Figures 1	 and	2	 give	examples	of	meta-
analysis	graphs.	Figure 1	 illustrates	a	graph	with	a	binary	
outcome	 variable	whereas	Figure 2	 depicts	 a	 forest	 plot	
with	 a	 continuous	 outcome	 variable.	 Some	 features	 of	
meta-analyses	using	binary	 and	 continuous	 variables	 and	
outcome	measures	are	compared	in	Table 2.
	 The	majority	 of	meta-analyses	 combine	 data	 from	
randomised	 controlled	 trials	 (RCTs),	which	 compare	 the	
outcomes	 between	 an	 intervention	 group	 and	 a	 control	
group.	While	outcomes	for	binary	variables	are	expressed	
as	 ratios,	 continuous	 outcomes	measures	 are	 usually	
expressed	as	‘weighted	mean	difference	(WMD)’	in	meta-
analyses	(Table 2).	
	 The	 details	 of	 the	 meta-analysis	 are	 commonly	
displayed	above	the	graph:
•	review:	 title/research	 question	 of	 the	 systematic	
review	and	meta-analysis	
•	comparison:	 intervention	 versus	 control	 group;	 a	
range	 of	 comparisons	may	 have	 been	 done	 in	 a	
systematic	review,	and
•	outcome:	 the	 primary	 outcome	measure	 analysed	
and	depicted	in	the	graph	below.
Meta-analysis	 graphs	 can	 principally	 be	 divided	 into	 six	
columns.	Individual	study	results	are	displayed	in	rows.	The	
first	column	(‘study’)	lists	the	individual	study	IDs	included	
in	 the	meta-analysis,	 usually	 the	 first	 author	 and	year	 are	
displayed.	The	 second	 column	 relates	 to	 the	 intervention	
groups,	and	the	third	column	to	the	control	groups.	
•	Figure 1:	 in	meta-analyses	with	 binary	 outcomes	
(eg.	disease/no	disease)	the	 individual	study	findings	
are	 displayed	 as	 ‘n/N’,	whereby:	 n	=	 the	number	 of	
participants	with	the	outcome	(eg.	Figure 1.	Adverse	
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effects)	 in	 the	 intervention	 (column	 2)	 or	
control	group	(column	3),	and	N	=	the	total	
number	 of	 participants	 in	 the	 intervention	
(column	2)	or	control	group	(column	3)	
•	Figure 2:	 in	meta-analyses	with	continuous	
outcome	 variables	 (eg.	 fasting	 blood	
glucose	 level)	 the	 individual	 study	 findings	
are	given	as	 ‘N’	and	 ‘mean	 (SD)',	whereby	
N	=	the	total	number	of	participants	 in	the	
intervention	 (column	 2)	 or	 control	 group	
(column	3),	and	mean	SD	=	 the	arithmetic	
mean	 and	 standard	 deviation	 (SD)	 of	 the	
outcome	measure	in	either	the	intervention	
(column	2)	or	control	group	(column	3).
The	 fourth	 column	 visually	 displays	 the	
study	 results.	The	 line	 in	 the	middle	 is	 called	
‘the	 line	 of	 no	 effect’,	which	 has	 the	 value	 of	
either	 1	 in	 case	 of	 a	 binary	 outcome	 variable	
(eg.	 odds	 ratio	 (OR)	 or	 relative	 risk	 [RR]),	 or	 0	
Figure 1. Meta-analysis of binary outcome measure
Review: Supplementation with M in condition X
Comparison: 01 Supplement M versus placebo
Outcome: 01 Adverse effects
Study Intervention group Control group Relative risk (fixed) Weight Relative risk (fixed)
 n/N n/N 95% CI (%) 95% CI 
Study A 1/141 2/142  17.8 0.50 [0.05, 5.49]
Study B 7/27 9/29  77.7 0.84 [0.36, 1.93]
Study C 1/100 0/100  4.5 3.00 [0.12, 72.77]
Total (95% CI) 268 271  100.0 0.87 [0.41, 1.87]
Total events: 9 (supplement M), 11 (control)
Test for heterogeneity Chi-square=0.79 df=2 p=0.67   I2=0.0%
Test for overall effect z=0.35   p=0.7
 0.01  0.1  1  10 100
 Favours intervention Favours control
Details of reviewStudy IDs
N = total number in group 
n = number in group with the outcome
Outcome effect measure 
Shown graphically and numerically
Fixed effect model used for meta-analysis
Influence of studies on 
overall meta-analysis
p value indicating level of 
statistical significance
Heterogeneity (I2) = diversity 
between studies Line of no effect
Scale of treatment effect
Overall effect
Table 1. Assessment of systematic reviews and meta-analyses
When can a systematic review and meta-analysis give further insight into primary 
study results?
•  Existing studies gave disparate results
•   Bigger study population (sample size) can increase power, generalisability and 
precision of findings (effect estimate)
•   Subgroup analyses may be possible and could generate new hypotheses
Is the meta-analysis clinically sensible?
•   Did the studies summarised in the systematic review address the same research 
question?
•   Are the studies included in the meta-analysis of comparable quality (selection bias, 
attrition rates, confounding variables)?
•   Are the studies comparable (eg. population, duration/dosage of treatment)?
Will the results help in caring for my patients?
•   Are the studied populations comparable to my patients?
•   Are the results clinically important?
•   Are all clinically important outcomes considered?
•  Were benefits, harms and costs considered?
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in	 case	 of	 a	 continuous	 outcome	 variable	 (eg.	
WMD).	There	 is	 no	 difference	 between	 the	
intervention	and	the	control	group,	if	OR	or	RR	
=	1	or	WMD	=	0.
	 The	 boxes	 are	 situated	 in	 line	 with	 the	
outcome	 value	 of	 the	 individual	 studies,	
also	 called	 the	 effect	 estimates	 (eg.	OR,	 RR	
or	WMD).	The	 value	 axis	 is	 at	 the	 bottom	 of	
the	 graph.	The	 size	 of	 the	 box	 is	 directly	
related	 to	 the	 'weighting'	 of	 the	 study	 in	 the	
meta-analysis.
	 The	 horizontal	 lines	 (whiskers)	 through	
the	 boxes	 depict	 the	 length	 of	 the	 confidence	
intervals	(CI).	The	longer	the	lines,	the	wider	the	
CI,	 the	 less	 precise	 the	 study	 results.	Arrows	
indicate	that	the	CI	is	wider	than	there	is	space	
in	the	graph.
	 The	 weight	 (in	 %)	 in	 the	 fifth	 column	
indicates	 the	 weighting	 or	 influence	 of	
the	 study	 on	 the	 overall	 results	 of	 the	meta-
analysis	 of	 all	 included	 studies.	The	 higher	
the	 percentage	weight,	 the	 bigger	 the	 box,	
the	 more	 influence	 the	 study	 has	 on	 the	
overall	 results.	The	 influence	 or	 ‘weight’	 of	
a	 study	 on	 the	 overall	 results	 is	 determined	
by	 the	 study’s	 sample	 size	 and	 the	 precision	
of	 the	 study	 results	 provided	 as	 a	 CI.	 In	
general,	 the	 bigger	 the	 sample	 size	 and	 the	




are	 identical	 to	 the	 graphical	 display	 in	 the	
fourth	column.
	 The	 diamond	 in	 the	 last	 row	 of	 the	 graph	
illustrates	 the	 overall	 result	 of	 the	 meta-




numerical	 results	 are	 given	 in	 column	 six.	
The	 total	 number	 of	 participants	 in	 the	
intervention	groups	(column	2)	and	the	control	
groups	 (column	 3)	 is	 also	 summarised	 in	 the	
same	row.	
	 If	 the	 diamond	 doesn’t	 cross	 the	 ‘line	 of	
no	 effect’,	 the	 calculated	 difference	 between	
the	 intervention	 and	 control	 groups	 can	
be	 considered	 as	 statistically	 significant.	
Numerically,	the	CI	does	not	include	1	for	binary	
outcome	variables,	measured	as	OR	or	RR;	the	
CI	 does	 not	 include	 0	 for	 continuous	 outcome	
variables,	measured	as	WMD.
	 Statistical	 significance	 of	 the	 overall	 result	
Figure 2. Meta-analysis of continuous outcome measures
Review: Medicines for condition X
Comparison: 01 Medicine Z versus placebo
Outcome: 01 Fasting blood glucose levels (mmol/L)
Study Intervention group Control group Weighted mean difference Weight WMD (fixed)
 N mean (SD) N mean (SD)  (fixed) 95% CI (%) 95% CI 
Study A 34  9.77 (2.93) 34  10.29 (3.43)  27.5 –0.52 [–2.04, 1.00]
Study B 36 8.40 (1.90) 36 8.90 (3.00)  46.9 –0.50 [–1.66, 0.66]
 Study C 30 10.26 (2.96) 30 12.09 (3.24)  25.6 –1.83 [–3.40, –0.26]
Total (95% CI) 100  100   100.0 –0.85 [–1.64, –0.05]
Test for heterogeneity Chi-square=2.03 df=2 p=0.36   I2=1.4%
Test for overall effect z=2.09   p=0.04
 –4.0  –2.0  0 2.0 4.0
 Favours intervention Favours control
Details of reviewStudy IDs
N = total number in group 
Mean (standard deviation) of outcome 
Outcome effect measure
Shown graphically and numerically
 Fixed effect model used for meta-analysis
Influence of studies on 
overall meta-analysis
p value indicating level ofstatistical 
significance
Heterogeneity (I2) = diversity 
between studies Line of no effect
Scale of treatment effect
Overall effect
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is	 also	 expressed	with	 the	 probability	 value	 (p	
value)	in	the	'test	for	overall	effect'.	Commonly,	
the	 result	 is	 regarded	as	 statistically	 significant	
if	p<0.05.	
	 It	 is	 important	 to	 always	 check	 the	 details	
on	 the	 value	 axis	 at	 the	 bottom	of	 the	 graph,	
as	 the	 orientation	 of	 the	 outcome	 values	 is	
not	 standardised.	 Some	 graphs	 display	 the	
intervention	 to	 the	 left	 side	 of	 the	 ‘line	 of	 no	
effect’,	 some	 to	 the	 right	 side	 (Table 2).	Also,	
one	 needs	 to	 be	 aware	 if	 the	meta-analysis	





At	 the	 bottom	 of	 the	 graph	 on	 the	 left	 hand	
side,	 the	number	of	 interest	 is	 the	 I2	 value.	 I2	
was	 only	 recently	 developed	 and	 introduced	
as	 the	 preferable	 and	more	 reliable	 test	 for	
heterogeneity.7	 I2	 ranges	 between	 0	 and	
100%.	Heterogeneity	measures	 the	 variability	
between	 studies,	 in	 other	 words	 it	 gives	
an	 indication	 how	 comparable	 studies	 in	
the	meta-analysis	 are.	 A	 useful	 visual	 guide	
to	 assess	 heterogeneity	 is	 to	 check	 the	
overlap	 of	 the	 CIs,	 ie.	 the	 horizontal	 lines	 or	
whiskers	 in	 the	meta-analysis	 graph.	 Studies	
are	 regarded	 as	 homogeneous	 if	 CIs	 of	 all	
studies	overlap.
	 Assessing	 inter-	 and	 intra-study	 variation	
or	 comparability	 of	 studies	 is	 important	 for	
the	 best	 choice	 of	meta-analysis	 technique	 or	
model.	Generally,	one	can	choose	between	two	
models	 of	meta-analysis,	 the	 'fixed'	 and	 the	
'random	 effect'	models.	 If	 I2<=25%,	 studies	
are	regarded	homogeneous	and	the	fixed	effect	




Fixed and random effect models
Generally,	 a	 fixed	 effect	model	 concentrates	
solely	 on	 the	 selected	 studies	 included	 in	
the	meta-analysis,	whereas	 a	 random	 effects	
model	 takes	 into	 account	 that	 there	might	
be	 other	 studies	 unpublished,	 overlooked	
in	 the	 systematic	 literature	 search,	 or	 to	
be	 undertaken	 in	 the	 future	 which	 weren’t	
included	 in	 the	 meta-analysis	 at	 hand.8	
Therefore,	 when	 the	 research	 question	 in	
the	meta-analysis	 is	 whether	 treatment	 has	
produced	an	effect	in	the	set	of	homogeneous	
studies	analysed,	 then	 the	 fixed	effects	model	
is	the	appropriate	one.9	
	 Choosing	 the	 right	model	 for	 analysis	 is	
particularly	 important	 if	 binary	 outcome	
variables	 are	 used,	 as	 fixed	 and	 random	
effects	models	 give	 different	 results.	 In	 case	
of	 continuous	 variables,	 the	 results	 of	meta-
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Table 2. Comparison of meta-analyses of either binary or continuous variables and outcome effect measures
  Binary Continuous
Examples for variables Yes/no, disease/no disease, alive/dead  Height, weight, blood pressure, serum 
cholesterol, walking speed
Outcome effect measure Ratios, often RR or OR Difference between means, often WMD
Line of no effect 1 0
Treatment scale
a)  If outcome effect measure is adverse  Favours intervention on left hand side Favours intervention on left hand side of 
 (eg. disease present, weight gain) or of treatment scale (ratio <1) treatment scale (WMD <0)
b)  if decreased outcome effect measure   
 is desirable (eg. lowered blood  
 pressure)  
Treatment scale
c) If outcome effect measure is desirable Favours intervention on right hand Favours intervention on right hand side of 
 (eg. stopped smoking, increased  side of treatment scale (ratio >1) treatment scale (WMD >0) 
 walking speed)  
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